コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 r 6 weeks, 76% (38 of 50; 95% confidence interval, 60%-85%) had SVR achieved 12 weeks after the end of treatment.
2 ained viral response, defined as HCV RNA concentration less than 15 IU/mL at 12 weeks after the end of treatment (SVR12).
3 The primary end point was sustained virologic response at 12 weeks after the end of treatment (SVR12).
4 h or without ribavirin achieved high sustained virological response rates at 12 weeks after the end of treatment and was generally well tolerated, with low rates
5 patients assessed, 54 (59%) achieved sustained virological response (SVR) at 12 weeks after the end of treatment, with a higher rate (73%; 35 of 48) in patients
9 t (interferon with or without ribavirin) and SVR (RNA test negative at least 12 weeks after the end of treatment) were determined.
10 s a sustained virologic response (an HCV RNA level of <25 IU per milliliter) 12 weeks after the end of treatment.
11 he primary endpoint was a sustained virological response (HCV RNA <25 IU/mL) 12 weeks after the end of treatment (SVR12).
12 The overall sustained virologic response rate 12 weeks after the end of treatment was 93.5% (186 of 199).
13 n an acceptable safety profile and high sustained virological response rates 12 weeks after the end of treatment (SVR12) in two phase 3 clinical trials in subjec
14 The primary endpoint was sustained virologic response 12 weeks after the end of treatment (SVR12) using intent-to-treat analysis.
15 s no significant effect of baseline RASs in NS5A on sustained viral response 12 weeks after the end of treatment (SVR12) with ledipasvir/sofosbuvir and only a sm
16 The primary efficacy endpoint was sustained virologic response 12 weeks after the end of treatment (SVR12).
17 The primary endpoint was sustained virologic response 12 weeks after the end of treatment (SVR12).
18 endpoint was the proportion of patients with sustained virological response 12 weeks after the end of treatment (SVR12).
19 alence of late recurrent viremia (patients with sustained virologic response 12 weeks after the end of treatment but detectable HCV RNA at follow-up week 24) and
20 After 24 weeks' treatment, sustained virological response 12 weeks after the end of treatment was achieved in 6 patients (60%).
21 9%) had an extended rapid virologic response; a sustained virologic response 12 weeks after the end of treatment was achieved in 95% and 93% of the patients, res
23 The primary efficacy end point was a sustained virologic response 12 weeks after the end of treatment.
25 3004 patients had detectable HCV RNA following sustained virologic response 12 weeks after the end of treatment.
26 The primary endpoint was SVR 12 weeks after the end of treatment (SVR12), for which 95% CIs were calculated with
27 240 participants completed 8 weeks of treatment and reached follow-up 12 weeks after the end of treatment.
28 eline, 6 to 8 weeks, 12 weeks (after which treatment stopped), and 24 weeks (12 weeks after the end of treatment).
30 ssessed clinical treatment success rates at a posttherapy evaluation visit (1-2 weeks after the end-of-treatment visit) were 85.5% (95% CI, 81.3% to 89.1%) in th
31 solated from blood before treatment, at weeks 4 and 12 during treatment, and 24 weeks after the end of treatment.
34 e was defined as an undetectable serum HCV RNA level (<50 IU per milliliter) 24 weeks after the end of treatment.
35 VR)-defined as HCV RNA levels below a designated threshold of quantification-24 weeks after the end of treatment (SVR24).
36 The primary endpoint was undetectable HCV RNA 24 weeks after the end of treatment (sustained virologic response [SVR]).
37 SVR (undetectable hepatitis C virus [HCV] RNA 24 weeks after the end of treatment) was determined on an intention-to-treat basis.
38 HCV RNA at 12 weeks) and sustained virologic response (undetectable HCV RNA 24 weeks after the end of treatment).
39 Although disability increased during the 24 weeks after the end of treatment, the advantage of PST over ST was retained.
40 Serum HCV RNA levels remained undetectable 24 weeks after the end of treatment in 84 patients (49 percent) in the combination-t
41 achieving SVR12, three relapsed, two achieved sustained virological response 4 weeks after the end of treatment but were lost to follow-up, and one was reinfect
42 ologically confirmed complete response at the post-treatment assessment visit 6 weeks after the end of treatment (a maximum of 30 weeks after treatment started).
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。